Currently, combination therapy with platinum-based chemotherapy and anti-PD-1/PD-L1 antibody is the standard of care for advanced NSCLC patients with PS 0-1 (especially PD-L1 < 50%). This evidence concerns the gene CD274 and non-small cell lung carcinoma.